Zhendong Chen

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al. · The Lancet Oncology · 2008 · 5.8K citations

Hepatology, Medicine, Cancer Management +12

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Zixian Wang, Chengxu Cui, Jun Yao et al. · Cancer Cell · 2022 · 523 citations · Full text

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Lin Shen, Ken Kato, Sung‐Bae Kim et al. · Journal of Clinical Oncology · 2022 · 293 citations · Full text